OSCOTECInc. Logo

OSCOTECInc.

Clinical-stage drug discovery for immunology, oncology, and neurodegenerative disorders.

039200 | KO

Overview

Corporate Details

ISIN(s):
KR7039200001
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 대왕판교로 700 A-901(삼평동,코리아바이오파크), 성남시

Description

Oscotec Inc. is a clinical-stage drug discovery and development company focused on translating scientific research into innovative medicines for clinically unmet needs. The company's development pipeline targets various diseases, with a primary focus on immunology, oncology, and neurodegenerative disorders. Key therapeutic areas include rheumatoid arthritis, immune thrombocytopenia, non-small cell lung cancer, acute myeloid leukemia, and Alzheimer's disease. Oscotec specializes in developing novel kinase inhibitors, such as Spleen Tyrosine Kinase (SYK) inhibitors, to address these conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-02-26 00:00
주주총회소집결의
Korean 7.3 KB
2024-02-26 00:00
주주총회집중일개최사유신고
Korean 5.3 KB
2024-02-21 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 93.3 KB
2024-02-08 00:00
주식등의대량보유상황보고서(일반)
Korean 91.3 KB
2024-01-22 00:00
소송등의제기ㆍ신청(경영권분쟁소송)(주주총회결의무효확인의소)
Korean 7.3 KB
2023-12-29 00:00
주식등의대량보유상황보고서(일반)
Korean 91.3 KB
2023-12-13 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2023-11-14 00:00
분기보고서 (2023.09)
Korean 1.2 MB
2023-10-10 00:00
기업설명회(IR)개최
Korean 6.8 KB
2023-09-14 00:00
투자판단관련주요경영사항(임상시험계획승인신청등결정)(알츠하이머 치료 후보물질 ADEL-Y01 임상 1a/1b상 임상시험계획 승인(IND))
Korean 10.2 KB
2023-08-17 00:00
투자판단관련주요경영사항(임상시험계획승인신청)(알츠하이머 치료 후보물질 ADEL-Y01 임상 1a/1b상 임상시험계획(IND) 신청)
Korean 8.8 KB
2023-08-14 00:00
[기재정정]사업보고서 (2022.12)
Korean 1.5 MB
2023-08-14 00:00
반기보고서 (2023.06)
Korean 1.1 MB
2023-07-07 00:00
주식등의대량보유상황보고서(일반)
Korean 90.4 KB
2023-07-07 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.2 KB

Automate Your Workflow. Get a real-time feed of all OSCOTECInc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OSCOTECInc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OSCOTECInc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.